Erectile Dysfunction Clinical Trial
Official title:
Effect of Testofen on Erectile Function in an Adult Male Population - A Double Blind, Randomised Controlled Trial.
This is a double blind, randomised, placebo-controlled clinical study with a 12-week participation and 3 groups (2 active groups and 1 placebo group) designed to monitor erectile function symptom severity and the effect Testofen may have on improving erectile function, sexual function, and quality of life.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | August 31, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years to 75 Years |
Eligibility | Inclusion Criteria: - Healthy male adults aged 40-75 years - Currently in a sexual relationship - Males with reduced erectile function (Score of <25 on IIEF) - BMI = 35 - Able to provide informed consent - Agree not to change current diet and exercise program while enrolled in this trial - Agree not to undertake another clinical trial while enrolled in this trial Exclusion Criteria: - History of prostate surgery and/or trauma - Receiving/prescribed treatment for erectile dysfunction, including oral medications, vacuum devices, constrictive devices, injections, or urethral suppositories - Receiving/prescribed treatment to increase/decrease testosterone levels e.g. androgens/anti androgens - Receiving/prescribed treatment to increase/decrease nitrate or nitric oxide levels - Unstable or serious illness (e.g. serious mood disorders, neurological disorders such as MS, kidney disease, liver disease, heart conditions, diabetes, hormone production disorders)* - All current malignancies (excluding BCC) or chemotherapy and/or radiotherapy treatment for malignancy within the previous 2 years - Receiving/prescribed [e.g., Coumadin or Marevan (warfarin), heparin, dalteparin, enoxaparin) or other anticoagulation therapy (e.g., thromboembolectomy or the use of vena cava filters) - Active smokers, nicotine use, alcohol, or drug (prescription or illegal substances) abuse - Chronic past and/or current alcohol use (>14 alcoholic drinks week) - Allergic to any of the ingredients in the active or placebo formula - Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion - Participants who have participated in any other related clinical study during the past 1 month a Any participant reporting having been told by their doctor that they have an under or over production of hormones (e.g., testosterone). *An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments. |
Country | Name | City | State |
---|---|---|---|
Australia | RDC Clinical Pty Ltd | Brisbane | Queensland |
Lead Sponsor | Collaborator |
---|---|
RDC Clinical Pty Ltd |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in International Index of Erectile Function (IIEF) questionnaire | The IIEF is a self-administered questionnaire in which participants will be asked to answer 15 questions relating to erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall sexual satisfaction. Lower scores indicated higher perceived erectile dysfunction | Baseline prior to commencement of study product, Week 4, Week 8 and Week 12 | |
Primary | Change in Erection Hardness Score (EHS) | Participants will be required to assess their erection quality by using the EHS. They will be asked to rate the hardness of their erection on a scale of one to four, with four being the maximal score. | Baseline prior to commencement of study product, Week 4, Week 8 and Week 12 | |
Secondary | Change in the Ageing Male Symptom (AMS) Questionnaire | The Ageing Males' Symptoms scale (AMS) is a self-administered questionnaire that will help assess the symptoms of ageing, often related to androgen decline. As the men in this population are aged between 40 and 75 years, this questionnaire will be used to assess any changes in quality of life. | Baseline prior to commencement of study product and Week 12 | |
Secondary | Change in Derogatis Interview for Sexual Functioning-Self Report (DISF-SR) | The DISF-SR is composed of 25 items and examines different aspects of human sexual functioning including sexual cognition and fantasy, sexual arousal, sexual behaviour and experiences, orgasm, and sexual drive and relationship. | Baseline prior to commencement of study product and Week 12 | |
Secondary | Change in cardiovascular health | Blood pressure (BP) as measured by automatic blood pressure machine | Baseline prior to commencement of study product and Week 12 | |
Secondary | Change in cardiovascular circulation | Doppler flow cytometry of the Femoral artery to assess circulation | Baseline prior to commencement of study product and Week 12 | |
Secondary | Change in height in anthropometry measurements | Height as measured by stadiometer in centimeters | Baseline prior to commencement of study product and Week 12 | |
Secondary | Change in weight in anthropometry measurements | Weight as measured by digital scales in kilograms | Baseline prior to commencement of study product and Week 12 | |
Secondary | Change in waist circumference in anthropometry measurements | Waist circumference as measured by tape in centimeters | Baseline prior to commencement of study product and Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 |